Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
Theodoros Karantanos(The University of Texas MD Anderson Cancer Center), Timothy C. Thompson(The University of Texas MD Anderson Cancer Center)
Cited by 879
Related Papers
Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models
|International Journal of Cancer|2017|50
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer
|Oncotarget|2016|29